Huaqing Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huaqing Jin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Guosheng Yin
Department of Statistics and Actuarial Science, The University of Hong Kong
12 shared publications - Fei Jiang
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA
5 shared publications - Chenyang Zhang
Department of Statistics and Actuarial Science, University of Hong Kong
4 shared publications - Srikantan S. Nagarajan
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
4 shared publications Ashish Raj
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
3 shared publicationsYijing Gao
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
3 shared publications
Latest Publications
- 23 December 2024
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 26 (1)
High-dimensional inference for functional regression with an application to the Alzheimer’s disease magnetoencephalography study
Summary: Alzheimer’s disease (AD) is a progressive, chronic neurodegenerative disorder affecting millions worldwide. A new clinical magnetoencephalography (MEG) study was conducted to identify neural activity biomarkers and key brain regions in AD. Traditional methods for analyzing MEG data, which typically extract features from power spectral density, suffer from information loss. Furthermore, functional regression with variable selection tends to produce non-robust results, making it less ideal for drawing reliable scientific conclusions. To address these challenges, we propose a high-dimensional hypothesis testing (HDHT) framework for functional covariates and introduce a rigorous inference process to support scientific conclusions. We establish the theoretical properties of the HDHT framework and validate its performance through simulation studies. Applying the HDHT framework to the AD MEG data, we identify 19 important regions associated with cognitive functions that align with established AD pathophysiology. These findings suggest that the non-invasive MEG can be a potential low-risk and low-toxicity modality for monitoring neurodegenerative progression.
- 23 December 2024
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 26 (1)
High-dimensional inference for functional regression with an application to the Alzheimer’s disease magnetoencephalography study
Summary: Alzheimer’s disease (AD) is a progressive, chronic neurodegenerative disorder affecting millions worldwide. A new clinical magnetoencephalography (MEG) study was conducted to identify neural activity biomarkers and key brain regions in AD. Traditional methods for analyzing MEG data, which typically extract features from power spectral density, suffer from information loss. Furthermore, functional regression with variable selection tends to produce non-robust results, making it less ideal for drawing reliable scientific conclusions. To address these challenges, we propose a high-dimensional hypothesis testing (HDHT) framework for functional covariates and introduce a rigorous inference process to support scientific conclusions. We establish the theoretical properties of the HDHT framework and validate its performance through simulation studies. Applying the HDHT framework to the AD MEG data, we identify 19 important regions associated with cognitive functions that align with established AD pathophysiology. These findings suggest that the non-invasive MEG can be a potential low-risk and low-toxicity modality for monitoring neurodegenerative progression.
- 26 September 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (29) , 5338-5352
Bayesian adaptive design for covariate‐adaptive historical control information borrowing
Interest in incorporating historical data in the clinical trial has increased with the rising cost of conducting clinical trials. The intervention arm for the current trial often requires prospective data to assess a novel treatment, and thus borrowing historical control data commensurate in distribution to current control data is motivated in order to increase the allocation ratio to the current intervention arm. Existing historical control borrowing adaptive designs adjust allocation ratios based on the commensurability assessed through study‐level summary statistics of the response agnostic of the distributions of the trial subject characteristics in the current and historical trials. This can lead to distributional imbalance of the current trial subject characteristics across the treatment arms as well as between current control data and borrowed historical control data. Such covariate imbalance may threaten the internal validity of the current trial by introducing confounding factors that affect study endpoints. In this article, we propose a Bayesian design which borrows and updates the treatment allocation ratios both covariate‐adaptively and commensurate to covariate dependently assessed similarity between the current and historical control data. We employ covariate‐dependent discrepancy parameters which are allowed to grow with the sample size and propose a regularized local regression procedure for the estimation of the parameters. The proposed design also permits the current and the historical controls to be similar to varying degree, depending on the subject level characteristics. We evaluate the proposed design extensively under the settings derived from two placebo‐controlled randomized trials on vertebral fracture risk in post‐menopausal women.
- 26 September 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (29) , 5338-5352
Bayesian adaptive design for covariate‐adaptive historical control information borrowing
Interest in incorporating historical data in the clinical trial has increased with the rising cost of conducting clinical trials. The intervention arm for the current trial often requires prospective data to assess a novel treatment, and thus borrowing historical control data commensurate in distribution to current control data is motivated in order to increase the allocation ratio to the current intervention arm. Existing historical control borrowing adaptive designs adjust allocation ratios based on the commensurability assessed through study‐level summary statistics of the response agnostic of the distributions of the trial subject characteristics in the current and historical trials. This can lead to distributional imbalance of the current trial subject characteristics across the treatment arms as well as between current control data and borrowed historical control data. Such covariate imbalance may threaten the internal validity of the current trial by introducing confounding factors that affect study endpoints. In this article, we propose a Bayesian design which borrows and updates the treatment allocation ratios both covariate‐adaptively and commensurate to covariate dependently assessed similarity between the current and historical control data. We employ covariate‐dependent discrepancy parameters which are allowed to grow with the sample size and propose a regularized local regression procedure for the estimation of the parameters. The proposed design also permits the current and the historical controls to be similar to varying degree, depending on the subject level characteristics. We evaluate the proposed design extensively under the settings derived from two placebo‐controlled randomized trials on vertebral fracture risk in post‐menopausal women.
- Open Access
- 11 September 2023
- Published by Elsevier in NeuroImage
- Vol. 281, 120358
Dynamic functional connectivity MEG features of Alzheimer’s disease
- 11 September 2023
- Published by Elsevier in NeuroImage
- Vol. 281, 120358
Open AccessDynamic functional connectivity MEG features of Alzheimer’s disease
- Open Access
- 27 July 2023
- Published by Elsevier in NeuroImage
- Vol. 279, 120278
Bayesian inference of a spectral graph model for brain oscillations
- 27 July 2023
- Published by Elsevier in NeuroImage
- Vol. 279, 120278
Open AccessBayesian inference of a spectral graph model for brain oscillations
- 24 April 2023
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (5) , 773-783
Time‐to‐event calibration‐free odds design: A robust efficient design for phase I trials with late‐onset outcomes
Compared with most of the existing phase I designs, the recently proposed calibration‐free odds (CFO) design has been demonstrated to be robust, model‐free, and easy to use in practice. However, the original CFO design cannot handle late‐onset toxicities, which have been commonly encountered in phase I oncology dose‐finding trials with targeted agents or immunotherapies. To account for late‐onset outcomes, we extend the CFO design to its time‐to‐event (TITE) version, which inherits the calibration‐free and model‐free properties. One salient feature of CFO‐type designs is to adopt game theory by competing three doses at a time, including the current dose and the two neighboring doses, while interval‐based designs only use the data at the current dose and is thus less efficient. We conduct comprehensive numerical studies for the TITE‐CFO design under both fixed and randomly generated scenarios. TITE‐CFO shows robust and efficient performances compared with interval‐based and model‐based counterparts. As a conclusion, the TITE‐CFO design provides robust, efficient, and easy‐to‐use alternatives for phase I trials when the toxicity outcome is late‐onset.
- 24 April 2023
- Published by Wiley in Pharmaceutical Statistics
- Vol. 22 (5) , 773-783
Time‐to‐event calibration‐free odds design: A robust efficient design for phase I trials with late‐onset outcomes
Compared with most of the existing phase I designs, the recently proposed calibration‐free odds (CFO) design has been demonstrated to be robust, model‐free, and easy to use in practice. However, the original CFO design cannot handle late‐onset toxicities, which have been commonly encountered in phase I oncology dose‐finding trials with targeted agents or immunotherapies. To account for late‐onset outcomes, we extend the CFO design to its time‐to‐event (TITE) version, which inherits the calibration‐free and model‐free properties. One salient feature of CFO‐type designs is to adopt game theory by competing three doses at a time, including the current dose and the two neighboring doses, while interval‐based designs only use the data at the current dose and is thus less efficient. We conduct comprehensive numerical studies for the TITE‐CFO design under both fixed and randomly generated scenarios. TITE‐CFO shows robust and efficient performances compared with interval‐based and model‐based counterparts. As a conclusion, the TITE‐CFO design provides robust, efficient, and easy‐to‐use alternatives for phase I trials when the toxicity outcome is late‐onset.
- Open Access
Bayesian Inference of a Spectral Graph Model for Brain Oscillations
The relationship between brain functional connectivity and structural connectivity has caught extensive attention of the neuroscience community, commonly inferred using mathematical modeling. Among many modeling approaches, spectral graph model (SGM) is distinctive as it has a closed-form solution of the wide-band frequency spectra of brain oscillations, requiring only global biophysically interpretable parameters. While SGM is parsimonious in parameters, the determination of SGM parameters is non-trivial. Prior works on SGM determine the parameters through a computational intensive annealing algorithm, which only provides a point estimate with no confidence intervals for parameter estimates. To fill this gap, we incorporate the simulation-based inference (SBI) algorithm and develop a Bayesian procedure for inferring the posterior distribution of the SGM parameters. Furthermore, using SBI dramatically reduces the computational burden for inferring the SGM parameters. We evaluate the proposed SBI-SGM framework on the resting-state magnetoencephalography recordings from healthy subjects and show that the proposed procedure has similar performance to the annealing algorithm in recovering power spectra and the spatial distribution of the alpha frequency band. In addition, we also analyze the correlations among the parameters and their uncertainty with the posterior distribution which can not be done with annealing inference. These analyses provide a richer understanding of the interactions among biophysical parameters of the SGM. In general, the use of simulation-based Bayesian inference enables robust and efficient computations of generative model parameter uncertainties and may pave the way for the use of generative models in clinical translation applications.
Open AccessBayesian Inference of a Spectral Graph Model for Brain Oscillations
The relationship between brain functional connectivity and structural connectivity has caught extensive attention of the neuroscience community, commonly inferred using mathematical modeling. Among many modeling approaches, spectral graph model (SGM) is distinctive as it has a closed-form solution of the wide-band frequency spectra of brain oscillations, requiring only global biophysically interpretable parameters. While SGM is parsimonious in parameters, the determination of SGM parameters is non-trivial. Prior works on SGM determine the parameters through a computational intensive annealing algorithm, which only provides a point estimate with no confidence intervals for parameter estimates. To fill this gap, we incorporate the simulation-based inference (SBI) algorithm and develop a Bayesian procedure for inferring the posterior distribution of the SGM parameters. Furthermore, using SBI dramatically reduces the computational burden for inferring the SGM parameters. We evaluate the proposed SBI-SGM framework on the resting-state magnetoencephalography recordings from healthy subjects and show that the proposed procedure has similar performance to the annealing algorithm in recovering power spectra and the spatial distribution of the alpha frequency band. In addition, we also analyze the correlations among the parameters and their uncertainty with the posterior distribution which can not be done with annealing inference. These analyses provide a richer understanding of the interactions among biophysical parameters of the SGM. In general, the use of simulation-based Bayesian inference enables robust and efficient computations of generative model parameter uncertainties and may pave the way for the use of generative models in clinical translation applications.
- Open Access
Dynamic functional connectivity MEG features of Alzheimer’s disease
Dynamic resting state functional connectivity (RSFC) characterizes time-varying fluctuations of functional brain network activity. While many studies have investigated static functional connectivity, it has been unclear whether features of dynamic functional connectivity are associated with neurodegenerative diseases. Popular sliding-window and clustering methods for extracting dynamic RSFC have various limitations that prevent extracting reliable features to address this question. Here, we use a novel and robust time-varying dynamic network (TVDN) approach to extract the dynamic RSFC features from high resolution magnetoencephalography (MEG) data of participants with Alzheimer’s disease (AD) and matched controls. The TVDN algorithm automatically and adaptively learns the low-dimensional spatiotemporal manifold of dynamic RSFC and detects dynamic state transitions in data. We show that amongst all the functional features we investigated, the dynamic manifold features are the most predictive of AD. These include: the temporal complexity of the brain network, given by the number of state transitions and their dwell times, and the spatial complexity of the brain network, given by the number of eigenmodes. These dynamic features have high sensitivity and specificity in distinguishing AD from healthy subjects. Intriguingly, we found that AD patients generally have higher spatial complexity but lower temporal complexity compared with healthy controls. We also show that graph theoretic metrics of dynamic component of TVDN are significantly different in AD versus controls, while static graph metrics are not statistically different. These results indicate that dynamic RSFC features are impacted in neurodegenerative disease like Alzheimer’s disease, and may be crucial to understanding the pathophysiological trajectory of these diseases.
Open AccessDynamic functional connectivity MEG features of Alzheimer’s disease
Dynamic resting state functional connectivity (RSFC) characterizes time-varying fluctuations of functional brain network activity. While many studies have investigated static functional connectivity, it has been unclear whether features of dynamic functional connectivity are associated with neurodegenerative diseases. Popular sliding-window and clustering methods for extracting dynamic RSFC have various limitations that prevent extracting reliable features to address this question. Here, we use a novel and robust time-varying dynamic network (TVDN) approach to extract the dynamic RSFC features from high resolution magnetoencephalography (MEG) data of participants with Alzheimer’s disease (AD) and matched controls. The TVDN algorithm automatically and adaptively learns the low-dimensional spatiotemporal manifold of dynamic RSFC and detects dynamic state transitions in data. We show that amongst all the functional features we investigated, the dynamic manifold features are the most predictive of AD. These include: the temporal complexity of the brain network, given by the number of state transitions and their dwell times, and the spatial complexity of the brain network, given by the number of eigenmodes. These dynamic features have high sensitivity and specificity in distinguishing AD from healthy subjects. Intriguingly, we found that AD patients generally have higher spatial complexity but lower temporal complexity compared with healthy controls. We also show that graph theoretic metrics of dynamic component of TVDN are significantly different in AD versus controls, while static graph metrics are not statistically different. These results indicate that dynamic RSFC features are impacted in neurodegenerative disease like Alzheimer’s disease, and may be crucial to understanding the pathophysiological trajectory of these diseases.
- Open Access
- 29 August 2022
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 31 (12) , 2310-2322
Approximate Bayesian computation design for phase I clinical trials
In the development of new cancer treatment, an essential step is to determine the maximum tolerated dose in a phase I clinical trial. In general, phase I trial designs can be classified as either model-based or algorithm-based approaches. Model-based phase I designs are typically more efficient by using all observed data, while there is a potential risk of model misspecification that may lead to unreliable dose assignment and incorrect maximum tolerated dose identification. In contrast, most of the algorithm-based designs are less efficient in using cumulative information, because they tend to focus on the observed data in the neighborhood of the current dose level for dose movement. To use the data more efficiently yet without any model assumption, we propose a novel approximate Bayesian computation approach to phase I trial design. Not only is the approximate Bayesian computation design free of any dose–toxicity curve assumption, but it can also aggregate all the available information accrued in the trial for dose assignment. Extensive simulation studies demonstrate its robustness and efficiency compared with other phase I trial designs. We apply the approximate Bayesian computation design to the MEK inhibitor selumetinib trial to demonstrate its satisfactory performance. The proposed design can be a useful addition to the family of phase I clinical trial designs due to its simplicity, efficiency and robustness.
- 29 August 2022
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 31 (12) , 2310-2322
Open AccessApproximate Bayesian computation design for phase I clinical trials
In the development of new cancer treatment, an essential step is to determine the maximum tolerated dose in a phase I clinical trial. In general, phase I trial designs can be classified as either model-based or algorithm-based approaches. Model-based phase I designs are typically more efficient by using all observed data, while there is a potential risk of model misspecification that may lead to unreliable dose assignment and incorrect maximum tolerated dose identification. In contrast, most of the algorithm-based designs are less efficient in using cumulative information, because they tend to focus on the observed data in the neighborhood of the current dose level for dose movement. To use the data more efficiently yet without any model assumption, we propose a novel approximate Bayesian computation approach to phase I trial design. Not only is the approximate Bayesian computation design free of any dose–toxicity curve assumption, but it can also aggregate all the available information accrued in the trial for dose assignment. Extensive simulation studies demonstrate its robustness and efficiency compared with other phase I trial designs. We apply the approximate Bayesian computation design to the MEK inhibitor selumetinib trial to demonstrate its satisfactory performance. The proposed design can be a useful addition to the family of phase I clinical trial designs due to its simplicity, efficiency and robustness.
- Open Access
- 22 March 2022
- Published by Elsevier in NeuroImage
- Vol. 254, 119131
Time-varying dynamic network model for dynamic resting state functional connectivity in fMRI and MEG imaging
- 22 March 2022
- Published by Elsevier in NeuroImage
- Vol. 254, 119131
Open AccessTime-varying dynamic network model for dynamic resting state functional connectivity in fMRI and MEG imaging
- Open Access
- 3 March 2022
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 31 (6) , 1051-1066
CFO: Calibration-free odds design for phase I/II clinical trials
Recent revolution in oncology treatment has witnessed emergence and fast development of the targeted therapy and immunotherapy. In contrast to traditional cytotoxic agents, these types of treatment tend to be more tolerable and thus efficacy is of more concern. As a result, seamless phase I/II trials have gained enormous popularity, which aim to identify the optimal biological dose (OBD) rather than the maximum tolerated dose (MTD). To enhance the accuracy and robustness for identification of OBD, we develop a calibration-free odds (CFO) design. For toxicity monitoring, the CFO design casts the current dose in competition with its two neighboring doses to obtain an admissible set. For efficacy monitoring, CFO selects the dose that has the largest posterior probability to achieve the highest efficacy under the Bayesian paradigm. In contrast to most of the existing designs, the prominent merit of CFO is that its main dose-finding component is model-free and calibration-free, which can greatly ease the burden on artificial input of design parameters and thus enhance the robustness and objectivity of the design. Extensive simulation studies demonstrate that the CFO design strikes a good balance between efficiency and safety for MTD identification under phase I trials, and yields comparable or sometimes slightly better performance for OBD identification than the competing methods under phase I/II trials.
- 3 March 2022
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 31 (6) , 1051-1066
Open AccessCFO: Calibration-free odds design for phase I/II clinical trials
Recent revolution in oncology treatment has witnessed emergence and fast development of the targeted therapy and immunotherapy. In contrast to traditional cytotoxic agents, these types of treatment tend to be more tolerable and thus efficacy is of more concern. As a result, seamless phase I/II trials have gained enormous popularity, which aim to identify the optimal biological dose (OBD) rather than the maximum tolerated dose (MTD). To enhance the accuracy and robustness for identification of OBD, we develop a calibration-free odds (CFO) design. For toxicity monitoring, the CFO design casts the current dose in competition with its two neighboring doses to obtain an admissible set. For efficacy monitoring, CFO selects the dose that has the largest posterior probability to achieve the highest efficacy under the Bayesian paradigm. In contrast to most of the existing designs, the prominent merit of CFO is that its main dose-finding component is model-free and calibration-free, which can greatly ease the burden on artificial input of design parameters and thus enhance the robustness and objectivity of the design. Extensive simulation studies demonstrate that the CFO design strikes a good balance between efficiency and safety for MTD identification under phase I trials, and yields comparable or sometimes slightly better performance for OBD identification than the competing methods under phase I/II trials.